OpenEvidence has achieved $300 million in annual recurring revenue (ARR) and serves 860,000 licensed clinicians in the United States. The company has raised $700 million in funding and previously closed a $250 million Series D round led by Thrive Capital and DST Global in January. Notably, OpenEvidence is approximately breaking even and considering strategic opportunities, such as a potential acquisition. The Information reported that OpenEvidence was in discussions to raise $200 million at a $20 billion valuation but might not proceed, citing concerns about shareholder dilution.